Sickle Cell Disease Market Insight, Epidemiology And Market Forecast - 2034The sickle cell disease treatment market is experiencing signific ...

I'm unvaxxed but for $20 mil I'd tell everyone to get the shot. Sorry not sorry. — Harry Berries (@MrHarryBerries) June 18, 2025 “Why does Pfizer need to pay Travis Kelce $20m,” asked ...

The lawmakers accuse Pfizer, Merck, J&J, AbbVie and Amgen of paying little to nothing in federal taxes despite generating billions of dollars annually.

Pfizer has experienced disappointing product and pipeline setbacks as well. It withdrew sickle cell disease therapy Oxbryta from the market last year after concluding that the benefits no longer ...

Regardless of which you choose, Pfizer's (NYSE: PFE) share price has declined during the period. Pfizer's dismal stock performance in recent years underscores the challenges the big drugmaker faces.